ImmunityBio Inc. (IBRX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

ImmunityBio Inc. (IBRX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.33

-0.15 (-6.05%)

At close: Jan 14, 2025, 3:59 PM

2.35

0.86%

Pre-market Jan 15, 2025, 06:23 AM EST

undefined% (undefined)

Bid	2.32
Market Cap	1.70B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.9
PE Ratio (ttm)	-2.59
Forward PE	n/a
Analyst	Buy

Ask	2.4
Volume	5,594,874
Avg. Volume (20D)	6,919,495
Open	2.49
Previous Close	2.48
Day's Range	2.28 - 2.54
52-Week Range	2.28 - 10.53
Beta	undefined

About IBRX

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 28, 2015

Employees 672

Stock Exchange NASDAQ

Ticker Symbol IBRX

Website https://immunitybio.com

Analyst Forecast

According to 4 analyst ratings, the average rating for IBRX stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 672.53% from the latest price.

Buy 50.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

ImmunityBio Inc. is scheduled to release its earnings on Mar 18, 2025, during market hours.
Analysts project revenue of $8.74M, reflecting a 6.19K% YoY growth and earnings per share of -0.26, making a -31.58% decrease YoY.

Why Price Moved

1 month ago · Source

-32.11%

ImmunityBio shares are trading lower after the com... Unlock content with Pro Subscription

1 month ago · Source

-3.33%

ImmunityBio shares are trading lower after the company proposed a public offering of common stock.

News

1 month ago · seekingalpha.com

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

ImmunityBio's recent $100M public offering was necessary to support ANKTIVA's commercialization and pipeline programs, despite the dilution and lower offering price of $3 per share. The company's cash...

1 month ago · seekingalpha.com

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

ImmunityBio's Anktiva shows promise with potential peak revenues of ~$900m annually, but faces significant competition and financial challenges, including a poorly timed $100m fundraising effort. Desp...

1 month ago · businesswire.com

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggr...

1 month ago · businesswire.com

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other conditions, shar...

1 month ago · zacks.com

Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 184.4% in ImmunityBio (IBRX). While the effectiveness of this highly sought-after metric is questionable, the p...

2 months ago · zacks.com

ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates

ImmunityBio (IBRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago.

2 months ago · businesswire.com

ImmunityBio Reports Third-Quarter 2024 Financial Results

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the third-quarter ended September 30, 2024. ANKTIVA® received a J-code (HCPCS Level II ...

2 months ago · seekingalpha.com

ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025

ImmunityBio's stock traded higher by 37% after dosing the first patient in its phase 1 QUILT 106 study for CD19+/CD20+ NHL, with data expected in 2025. The company's ANKTIVA therapy, combined with Key...

2 months ago · zacks.com

ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock?

ImmunityBio (IBRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the...

2 months ago · benzinga.com

800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio

EF Hutton has initiated coverage on ImmunityBio Inc. IBRX, a vertically integrated biotechnology company developing therapies and vaccines to bolster the natural immune system for cancers and infectio...

2 months ago · businesswire.com

ImmunityBio to Participate in the Jefferies London Healthcare Conference

CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that company executives will be participating in the Jefferies London Healthcare Confere...